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In conclusion, RF abnormalities in runners were caused by dehydration,
protein catabolism, rhabdomyolysis and others. These RF changes were not
present or parameters not signiﬁcantly differed from initial values 2 days
after both runs. Plasma AGEs and AOPPs in runners were in reference
ranges, no signiﬁcant changes during the both runs were observed.
http://dx.doi.org/10.1016/j.krcp.2012.04.495
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A POPULATION PHARMACOKINETIC (PK)- PHARMACODYNAMIC (PD)
ANALYSIS OF PEGINESATIDE INDIA LYSIS PATIENTS WITH CHRONIC
KIDNEY DISEASE
Himanshu Naik, Max Tsai, Ping Qiu, Majid Vakilynejad
Takeda Global Research & Development Ctr, Inc., Deerﬁeld, IL, USA
Peginesatide is an erythropoiesis stimulating agent (ESA) being developed for
the treatment of anemia due to chronic kidney disease in dialysis patients. The
purpose of this analysis was to develop a population PK-PD model to
characterize time-course of peginesatide plasma and hemoglobin (Hb)
concentrations following administration of IV and SC peginesatide injections.
This population PK–PD analysis included 4 phase 2 studies and 1 phase 3 study.
Baseline subject demographics, laboratory values, and concomitant
medications were evaluated as covariates in a stepwise manner. Models were
evaluated for goodness-of-ﬁt using diagnostic plots, predictability based on
visual predictive check, and stability based on bootstrap analyses. The ﬁnal PK
model was a two compartment model with ﬁrst-order absorption and
saturable elimination. The ﬁnal PD model was a precursor-dependent indirect
response model with parameters accounting for the residual effect from the
previous ESA doses (ESAD) and apparent change in disease condition (CF). The
PD parameters shown below were estimated with good precision(relative
standard error[RSE] r2%).
Parameters Estimate RSE%
EC50 (ng/mL) 401 2.0
Emax 0.542 1.6
Baseline Hb (g/dL) 11.5 0.40
MTT (mean transit time for red blood cells, h) 1640 0.49
MTP (mean transit time for progenitor cells, h) 462 1.1
ESA (residual effect from the previous ESA 0.153 0.66
CF (correction factor for disease condition) 0.000275 0.87
Total bilirubin, body mass index, age, alkaline phosphatase, ethnicity, and
serum creatinine (for non-dialysis subjects) for PK and age and ESAD for PD
were identiﬁed as statistically signiﬁcant (p-valueo0.005) covariates.
None of these identiﬁed covariates were considered to be clinically
relevant, based on their impact on simulated peginesatide exposure
(o730%) and Hb (o0.2 g/dL) levels.
http://dx.doi.org/10.1016/j.krcp.2012.04.496
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PUTATIVE ROLE OF FGF 23 IN THE DEVELOPMENT OF
HYPOPHOSPHATEMIA AND BONE FRUCTURES IN AN ANEMIC PATIENT
TREATED BY INTRAVENOUS SACCHARATED FERRIC OXIDE
Risa Ishida, Shohei Nakanishi, Sachie Hisose, Jong Il Kim
Masafumi Fukagawa Chibune Hospital, Osaka city, JAPAN
A post-menopausal patient with normal kidney function was referred to
our hospital because of severe lumber pain. She had been treated by
initially oral, and then by intravenous iron for longer than ﬁve years for the
treatment of iron deﬁciency anemia due to recurrent GI bleeding. On
admission, multiple lumber bone fracture with low bone mineral density
was conﬁrmed. Laboratory tests revealed severe hypophosphatemia (1.6
mg/dl) with slight decrease of calcium ion level. Serum levels of 25D and
1,25D were low normal, while increase of intact PTH (83.9 pg/ml) and
FGF23 (60 pg/ml) were observed. After terminating intravenous iron
supplement, her symptoms and hypophsophatemia were gradually
normalized with oral active vitamin D treatment. Although we could not
completely exclude the contribution of disturbed iron absorption from the
intestine, damages of proximal tubular cells by iron, and osteomalacia
caused by the deposition of iron, increased FGF23 level may have played
critical roles in the development of severe hypophosphatemia in this
patient. Such hypophosphatemia due to high FGF23 has recently been
reported in patients treated by intravenous sacharated ferric oxide.
http://dx.doi.org/10.1016/j.krcp.2012.04.497
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THE EATING AT TREATMENT (EAT) QUESTIONNAIRE: A TOOL TO ASSESS
HABITS RELATED TO PATIENTS EATING AT DIALYSIS
Mary Burgess 1, Maria Stasios 2, Marcia Davis 2, Deborah Benner 2
1
DaVita Clinical Research, Minneapolis, MN
2
DaVita Inc, Denver, CO, USA
Within the US, the policies at dialysis facilities differ as to whether patients
(pts) are permitted to eat or not while being treated. The Eating At Treatment
(EAT) pilot program was designed to determine whether educating pts and
allowing them to eat on dialysis would reduce the number of missed meals on
dialysis days and potentially improve nutritional status. The EAT questionnaire
was developed as a tool to assess eating habits of pts on days they received
dialysis treatment vs non-treatment days. Seven Registered Dietitians (RDs)
administered the EAT questionnaire to 61 pts.
Patients reported eating a different number of meals/day (2.32 vs 2.69) and
snacks/day (1.09 vs 1.36) on treatment vs non-treatment days, respectively. Of
the pts who ate at the dialysis facility, 86% reported that they ate during
treatment as opposed to before or after treatment. Of the pts who did not eat at
the dialysis facility, the most common reported reasons were that they were
not hungry (63%) or reported an adverse event (eg., stomach pain, risk of
diarrhea, hypotension) (20%). Reported dietary intake from 37 pts who ate
during dialysis was scored by RDs for protein and kcal content. Adequate intake
was set at 4 200 kcal for calorie intake and 4 10 g of protein for protein
intake. Nineteen (51%) pts reported adequate kcal intake, while only 12 (32%)
pts reported adequate protein intake.
Based on results obtained from this small pilot questionnaire, pts reported
eating less on treatment days vs non-treatment days. In addition, pts reported
that their intake at treatment was low in protein. This questionnaire has proven
to be an effective tool that is easy to administer and score (total time 12min/
pt) for providing insight into the eating habits of pts receiving dialysis
treatment. An opportunity exists for educating pts through nutritional
counseling about increasing their protein and kcal intake on treatment days.
Distribution of this questionnaire to a large number of dialysis pts may prove
useful for reevaluating policies regarding eating at dialysis centers.
http://dx.doi.org/10.1016/j.krcp.2012.04.498
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PRACTICES AND OPINIONS ON IN-CENTER FOOD CONSUMPTION ACROSS
1,223 FACILITIES IN THE UNITED STATES
Deborah Benner 1, Marcia Davis 1, Maria Stasios 1, Mary Burgess 2
1
DaVita Inc, Denver, CO
2
DaVita Clinical Research, Minneapolis, MN
In the United States, the practices and opinions of healthcare providers
regarding eating on dialysis are unknown. The purpose of this study was to
understand healthcare provider opinions and in-center hemodialysis
patient practices regarding eating while at the dialysis center. In June 2011,
over 1200 registered dietitians within a large dialysis organization in the
US were surveyed on current practices and opinions of patient food
consumption during dialysis treatment using an online survey.
1223 of 1665 (73%) dialysis facilities responded to the food consumption
survey.
n¼1222 Permitted No Guidelines Not allowed
n (%) n (%) n (%)
Eating on dialysis 803 (66%) 67 (5%) 352 (29%)
Drinking on dialysis 907 (75%) 87 (7%) 228 (19%)
218 (18%) of the respondents stated that the facility practice for
consuming nutritional supplements (eg., liquid nutritional supplements
and/or protein bars) while on dialysis was different than the policy for
consuming food while on dialysis. Interestingly, 1203 (98%) of the
respondents stated consuming food before or after dialysis was allowed.
The top reasons for facility practices that allowed eating during dialysis
were: prevention of hypoglycemia on dialysis, improved kcal intake on
dialysis days, and the opportunity to provide counseling on food products
currently chosen by the patient. The top reasons for facility practices not
permitting eating during dialysis included: potential adverse events
associated with hypotension, GI symptoms, choking, infection, pest control,
and spills. Further analyses are warranted to determine whether there is a
correlation between allowing patients to eat during dialysis treatment and
an improvement in the nutritional status of the patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.499
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